Physician profile
John E Gurrieri
NPI 1528137122
$2,057.24
in general payments reported to CMS, 2019-2025
33 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $40.26 · 2021: $278 · 2022: $978 · 2023: $478 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $234.04 | 2022 | |
| Novo Nordisk INC | $198.53 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $174.32 | 2021-2023 | Mounjaro |
| Abbvie INC. | $117.90 | 2021-2023 | |
| Astellas Pharma US INC | $113.48 | 2021-2023 | Veozah, Myrbetriq |
| Almatica Pharma LLC | $110.82 | 2021-2023 | Sertraline Hcl, Loreev Xr, Gralise |
| Pfizer INC. | $106.84 | 2019-2025 | |
| Abbott Laboratories | $102.57 | 2022-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $92.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $91.82 | 2022-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $84.59 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $71.89 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $62.80 | 2022-2023 | Eliquis |
| Astrazeneca Pharmaceuticals Lp | $56.50 | 2021-2025 | Airsupra |
| Teva Pharmaceuticals USA, INC. | $52.37 | 2021-2023 | Airduo Digihaler |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $48.09 | 2023 | Rexulti |
| Gilead Sciences, INC. | $36.64 | 2022-2023 | |
| Viiv Healthcare Company | $29.49 | 2022 | |
| Amgen INC. | $27.71 | 2022 | |
| Sanofi Pasteur INC. | $27.45 | 2019-2023 | |
| Eisai INC. | $26.49 | 2021 | |
| Alkermes, INC. | $25.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.66 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.76 | 2022 | |
| Philips North America LLC | $15.41 | 2019 | |
| Daiichi Sankyo INC. | $14.92 | 2019 | |
| Adlon Therapeutics L.P. | $14.68 | 2021 | |
| Esperion Therapeutics, INC. | $14.55 | 2022 | |
| Amarin Pharma, INC. | $13.88 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.48 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.33 | 2022 | |
| Allergan, INC. | $12.11 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gurrieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.